Targeted DNA sequencing of non-small cell lung cancer identifies mutations associated with brain metastases
Open Access
- 25 May 2018
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (40) , 25957-25970
Abstract
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> George D. Wilson1, 2, Matthew D. Johnson1, 4, Samreen Ahmed2, Paola Yumpo Cardenas3, Inga S. Grills1 and Bryan J. Thibodeau2 1Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI, USA 2Beaumont BioBank, William Beaumont Hospital, Royal Oak, MI, USA 3Cancer Genetics Program, William Beaumont Hospital, Royal Oak, MI, USA 4Department of Radiation Oncology, McLaren Health Care, Macomb, MI, USA Correspondence to: George D. Wilson, email: george.wilson@beaumont.edu Keywords: non-small cell lung cancer; brain metastases; next generation DNA sequencing; targeted agents; radiotherapy Received: January 15, 2018 Accepted: April 24, 2018 Published: May 25, 2018 ABSTRACT Introduction: This study explores the hypothesis that dominant molecular oncogenes in non-small cell lung cancer (NSCLC) are associated with metastatic spread to the brain. Methods: NSCLC patient groups with no evidence of metastasis, with metastatic disease to a non-CNS site, who developed brain metastasis after diagnosis, and patients with simultaneous diagnosis of NSCLC and metastatic brain lesions were studied using targeted sequencing. Results: In patients with brain metastasis versus those without, only 2 variants (one each in BCL6 and NOTHC2) were identified that occurred in ≥ 4 NSCLC of patients with brain metastases but ≤ 1 of the NSCLC samples without brain metastases. At the gene level, 20 genes were found to have unique variants in more than 33% of the patients with brain metastases. When analyzed at the patient level, these 20 genes formed the basis of a predictive test to discriminate those with brain metastasis. Further analysis showed that PI3K/AKT signaling is altered in both the primary and metastases of NSCLC patients with brain lesions. Conclusion: While no single variant was associated with brain metastasis, this study describes a potential gene panel for the identification of patients at risk and implicates PI3K/AKT signaling as a therapeutic target.Keywords
This publication has 54 references indexed in Scilit:
- A Nomogram to Predict Brain Metastases of Resected Non-Small Cell Lung Cancer PatientsAnnals of Surgical Oncology, 2016
- A nomogram to predict brain metastasis as the first relapse in curatively resected non-small cell lung cancer patientsLung Cancer, 2015
- Development and Validation of a Nomogram for Predicting Survival in Patients With Resected Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2015
- Prophylactic Cranial Irradiation: Recent Outcomes and InnovationsCNS Oncology, 2014
- Molecular determinants of lung cancer metastasis to the central nervous system.2013
- Factors associated with the development of brain metastasesCancer, 2010
- Diagnosis-Specific Prognostic Factors, Indexes, and Treatment Outcomes for Patients With Newly Diagnosed Brain Metastases: A Multi-Institutional Analysis of 4,259 PatientsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Clinical Predictors of Metastatic Disease to the Brain from Non–Small Cell Lung Carcinoma: Primary Tumor Size, Cell Type, and Lymph Node MetastasesRadiology, 2007
- A Phase II Trial of Temozolomide for Patients with Recurrent or Progressive Brain MetastasesJournal of Neuro-Oncology, 2001
- Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancerLung Cancer, 1998